Over the weekend, telemedicine company Hims & Hers decided to shelve its plan to launch a US$49 compound weight-loss pill due to legal action from Novo Nordisk and a warning from the U.S. Food and Drug Administration (FDA). As a result, Novo Nordisk's stock, listed in Frankfurt, rose by 4.5% on Monday. The core ingredient of this weight-loss pill is the same as that of Novo Nordisk's blockbuster drug, sparking opposition after its release. Previously, the FDA commissioner had stated that such compound drugs would be targeted, leading to a rebound of over 5% in Novo Nordisk's stock price last Friday. Despite the renewed rise in stock price, Novo Nordisk still faces competition from Eli Lilly and the impact of low-cost compound alternatives. Earlier, the company reported experiencing 'unprecedented price pressure,' which caused its stock price to plummet by 17%, with its market value evaporating by nearly two-thirds since peaking in June 2024.